| Literature DB >> 31410696 |
Deborah A Bilder1,2, M Sean Esplin3,4, Hilary Coon3, Paul Burghardt5, Erin A S Clark3, Alison Fraser3,6, Ken R Smith3,6, Whitney Worsham3, Katlin Chappelle5, Thomas Rayner3, Amanda V Bakian3.
Abstract
Epidemiologic studies link increased autism spectrum disorder (ASD) risk to obstetrical conditions associated with inflammation and steroid dysregulation, referred to as prenatal metabolic syndrome (PNMS). This pilot study measured steroid-related biomarkers in early second trimester maternal serum collected during the first and second trimester evaluation of risk study. ASD case and PNMS exposure status of index offspring were determined through linkage with autism registries and birth certificate records. ASD case (N = 53) and control (N = 19) groups were enriched for PNMS exposure. Higher estradiol and lower sex hormone binding globulin (SHBG) were significantly associated with increased ASD risk. Study findings provide preliminary evidence to link greater placental estradiol activity with ASD and support future investigations of the prenatal steroid environment in ASD.Entities:
Keywords: Autism; Biomarkers; Metabolic syndrome; Prenatal risk factors
Mesh：
Substances：
Year: 2019 PMID： 31410696 PMCID： PMC6814559 DOI： 10.1007/s10803-019-04162-2
Source DB: PubMed Journal: J Autism Dev Disord ISSN： 0162-3257